Abiraterone plus Prednisone in Metastatic, Castration-Sensitive ...
网页2017年6月4日 · Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of...
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
网页2023年2月16日 · Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA...
Accueil - Fizazi & Associés
网页2014年12月13日 · Fizazi & Associés offre à ses clients un vaste éventail de services juridiques pour répondre à leurs besoins récurrents ou ponctuels. Les équipes en place comptent plusieurs années d'expertise en services juridiques offerts aussi bien aux entreprises qu’aux particuliers. EN SAVOIR PLUS. Audit et certification.
Karim Fizazi | Gustave Roussy
网页Karim Fizazi is leading major studies in oncology: role of denosumab in the prevention of complications of bone metastases of prostate cancer, impact of chemotherapy combined with standard of care on relapse-free survival in patients with localized and high-risk prostate cancer (GETUG 12 study), new standard of care for young patients with ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel …
网页2023年2月16日 · Fizazi K, Foulon S, Carles J, et al: Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. Lancet 399:1695-1707, 2022
Abiraterone plus prednisone added to androgen deprivation …
网页2022年4月30日 · Electronic address: karim.fizazi@gustaveroussy.fr. 2 Department of Biostatistics and Epidemiology, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, Ligue Contre le Cancer, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Darolutamide and Survival in Metastatic, Hormone-Sensitive …
网页2022年2月17日 · Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final...
Editorial Team: Karim Fizazi: European Urology
网页Fizazi is associate editor of European Journal of Cancer and consulting editor of European Urology. Furthermore, he has published more than 300 peer-reviewed articles.
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in
网页Dr. Fizazi put the PEACE-1 results into context with previous randomized Phase 3 studies for first-line therapy in high-volume de novo mCSPC. Median OS ranged from 33 to 35 months for ADT alone, 40 to 48 months for ADT plus Docetaxel, and 50 to …
Karim Fizazi, MD, PhD - Targeted Oncology
网页Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer. The Addition of Darolutamide to ADT Reduces Risk of Metastasis in Nonmetastatic CRPC